Correlation Between Codiak BioSciences and Scopus Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Codiak BioSciences and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Codiak BioSciences and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Codiak BioSciences and Scopus Biopharma, you can compare the effects of market volatilities on Codiak BioSciences and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Codiak BioSciences with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Codiak BioSciences and Scopus Biopharma.

Diversification Opportunities for Codiak BioSciences and Scopus Biopharma

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Codiak and Scopus is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Codiak BioSciences and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Codiak BioSciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Codiak BioSciences are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Codiak BioSciences i.e., Codiak BioSciences and Scopus Biopharma go up and down completely randomly.

Pair Corralation between Codiak BioSciences and Scopus Biopharma

If you would invest  10.00  in Scopus Biopharma on September 1, 2024 and sell it today you would earn a total of  0.00  from holding Scopus Biopharma or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy0.0%
ValuesDaily Returns

Codiak BioSciences  vs.  Scopus Biopharma

 Performance 
       Timeline  
Codiak BioSciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Codiak BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable forward-looking signals, Codiak BioSciences is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors.
Scopus Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Scopus Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Scopus Biopharma is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Codiak BioSciences and Scopus Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Codiak BioSciences and Scopus Biopharma

The main advantage of trading using opposite Codiak BioSciences and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Codiak BioSciences position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.
The idea behind Codiak BioSciences and Scopus Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.